



L5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2010:845041 CAPLUS Full-text
 DN 153:175010
 TI Preparation of tricyclic heteroaryl compounds as squalene synthase inhibitors
 IN Sugita, Kazuyuki; Otsuka, Masaki; Oki, Hitoshi; Haginoya, Noriyasu; Ichikawa, Masanori; Ota, Masahiro; Shibata, Norihiro
 PA Daiichi Sankyo Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 277pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | JP 2010150142 | A | 20100708 | JP 2007-115164 | 20070425 |
| | WO 2008132846 | A1 | 20081106 | WO 2008-JP1073 | 20080424 |
| | W: | | | | |
| | AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| | RW: | | | | |
| | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | JP 2007-115164 | A | 20070425 | | |
| GI | | | | | |



AB Title compds., e.g., I [or pharmaceutically acceptable salts or solvates thereof], etc., were prepared For example, reaction of compound II (preparation given) with NH₂NH₂·H₂O followed by in-situ treatment with trifluoroacetic anhydride, de-allylation, ethylation, and hydrolysis afforded compound I. In squalene synthase inhibition assays, the IC₅₀ of I was 0.98 nM. The invention compds. are claimed useful for the treatment of hypercholesterolemia, hyperlipidemia, etc.

IT 1075688-02-6P 1075688-08-2P 1075688-16-2P
 1075688-22-0P 1075688-24-2P 1075688-30-0P
 1075688-36-6P 1075688-39-9P 1075688-53-7P

1075688-64-0P 1075688-83-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic heteroaryl compds. as squalene synthase inhibitors)

RN 1075688-02-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-ethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-08-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2-chloro-3-ethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-16-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-ethoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-22-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-ethoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-24-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2,3-dimethoxyphenyl)-8-(trifluoromethoxy)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-30-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-[3-(difluoromethoxy)-2-methoxyphenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-36-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(3-ethoxy-2-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-39-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(2-ethyl-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-53-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-64-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-1-(1,1-difluoroethyl)-6-(3-methoxy-2-methylphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-83-3 CAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 1075688-01-5P 1075688-07-1P 1075688-15-1P
1075688-21-9P 1075688-23-1P 1075688-29-7P
1075688-35-5P 1075688-38-8P 1075688-52-6P
1075688-63-9P 1075688-82-2P 1234205-62-9P
1234206-00-8P 1234206-02-0P 1234206-04-2P
1234206-06-4P 1234206-72-4P 1234206-74-6P
1234206-75-7P 1234206-76-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic heteroaryl compds. as squalene synthase inhibitors)

RN 1075688-01-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-ethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-07-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2-chloro-3-ethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-15-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-ethoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-21-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-ethoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-23-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2,3-dimethoxyphenyl)-8-(trifluoromethoxy)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-29-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-[3-(difluoromethoxy)-2-methoxyphenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-35-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(3-ethoxy-2-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-38-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(2-ethyl-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-52-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-63-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-1-(1,1-difluoroethyl)-6-(3-methoxy-2-methylphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-82-2 CAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1234205-62-9 CAPLUS

CN 1-Piperazinebutanoic acid, 4-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-γ-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1234206-00-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-bromo-6-(2-chloro-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1234206-02-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-bromo-1-(chlorodifluoromethyl)-6-(2-chloro-3-methoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1234206-04-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-bromo-6-(2-chloro-3-methoxyphenyl)-1-(1,1-difluoroethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1234206-06-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-chloro-3-methoxyphenyl)-8-cyano-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1234206-72-4 CAPLUS

CN 3-Azetidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1234206-74-6 CAPLUS

CN 2-Azetidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1234206-75-7 CAPLUS


CN 2-Azetidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1234206-76-8 CAPLUS
 CN Acetic acid, 2-[[1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyloxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 1234205-54-9P 1234205-63-0P 1234205-64-1P
 1234206-01-9P 1234206-03-1P 1234206-05-3P
 1234206-07-5P 1234206-73-5P 1234206-77-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of tricyclic heteroaryl compds. as squalene synthase inhibitors)
 RN 1234205-54-9 CAPLUS
 CN 1-Piperazinebutanoic acid, 4-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-γ-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1234205-63-0 CAPLUS

CN 1-Piperazinebutanoic acid, 4-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-γ-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 1234205-64-1 CAPLUS


CN 1-Piperazinebutanoic acid, 4-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-γ-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 1234206-01-9 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-bromo-6-(2-chloro-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1234206-03-1 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-bromo-1-(chlorodifluoromethyl)-6-(2-chloro-3-methoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1234206-05-3 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-bromo-6-(2-chloro-3-methoxyphenyl)-1-(1,1-difluoroethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1234206-07-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-chloro-3-methoxyphenyl)-8-cyano-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1234206-73-5 CAPLUS

CN 3-Azetidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1234206-77-9 CAPLUS


CN Acetic acid, 2-[[1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyloxy]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2010:559861 CAPLUS Full-text
 DN 152:525883
 TI Preparation of tricyclic heteroaryl compounds as squalene synthase inhibitors
 IN Sugita, Kazuyuki; Otsuka, Masaki; Oki, Hitoshi; Haginoya, Noriyasu; Ichikawa, Masanori; Ota, Masahiro; Shibata, Norihiro
 PA Daiichi Sankyo Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 154pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | JP 2010100566 | A | 20100506 | JP 2008-273706 | 20081024 |
| PRAI | JP 2008-273706 | | 20081024 | | |
| GI | | | | | |



AB Title compds., e.g., I [or pharmaceutically acceptable salts or solvates thereof], etc., were prepared For example, reaction of compound II (preparation given) with $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ followed by in-situ treatment with trifluoroacetic anhydride, de-allylation, ethylation, and hydrolysis afforded compound I. In squalene synthase inhibition assays, the IC_{50} of I was 0.98 nM. The invention compds. are claimed useful for the treatment of hypercholesterolemia, hyperlipidemia, etc.

IT 1075688-02-6P 1075688-08-2P 1075688-16-2P
 1075688-22-0P 1075688-24-2P 1075688-30-0P
 1075688-36-6P 1075688-39-9P 1075688-53-7P
 1075688-64-0P 1075688-83-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic heteroaryl compds. as squalene synthase inhibitors)

RN 1075688-02-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-ethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-08-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2-chloro-3-ethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-16-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-ethoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-22-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-ethoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-24-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2,3-dimethoxyphenyl)-8-(trifluoromethoxy)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-30-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-[3-(difluoromethoxy)-2-methoxyphenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-36-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(3-ethoxy-2-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-39-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(2-ethyl-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-53-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-64-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-1-(1,1-difluoroethyl)-6-(3-methoxy-2-methylphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-83-3 CAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 1075688-01-5P 1075688-07-1P 1075688-15-1P
 1075688-21-9P 1075688-23-1P 1075688-29-7P
 1075688-35-5P 1075688-38-8P 1075688-52-6P
 1075688-63-9P 1075688-82-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of tricyclic heteroaryl compds. as squalene synthase
 inhibitors)

RN 1075688-01-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-
 ethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-
 a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX
 NAME)


Absolute stereochemistry.



RN 1075688-07-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-
 (2-chloro-3-ethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-
 yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-15-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-ethoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-21-9 CAPLUS


CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-ethoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1075688-23-1 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2,3-dimethoxyphenyl)-8-(trifluoromethoxy)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1075688-29-7 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-[3-(difluoromethoxy)-2-methoxyphenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1075688-35-5 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(3-ethoxy-2-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-38-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(2-ethyl-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-52-6 CAPLUS


CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1075688-63-9 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-1-(1,1-difluoroethyl)-6-(3-methoxy-2-methylphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1075688-82-2 CAPLUS
 CN 3-Pyrrolidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2010:500524 CAPLUS Full-text
 DN 152:477157
 TI Preparation of tricyclic heteroaryl compounds as squalene synthase inhibitors
 IN Sugita, Kazuyuki; Ota, Masahiro
 PA Daiichi Sankyo Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 71pp.
 CODEN: JKXXAF
 DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | JP 2010090078 | A | 20100422 | JP 2008-263475 | 20081010 |
| PRAI | JP 2008-263475 | | 20081010 | | |
| GI | | | | | |



AB Title compds., e.g., I [or their pharmacol. acceptable salts], etc., were prepared For example, reaction of Et [(trans)-7-chloro-5-[3-methoxy-2-(trifluoromethyl)phenyl]-2-thioxo-1,2,3,5- tetrahydro-4,1-benzoxazepin-3-yl]acetate (preparation given) with $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ followed by cyclization with trifluoroacetic anhydride, separation using chiral HPLC and hydrolysis afforded (4R,6R)-I. In squalene synthase inhibition assays, the IC_{50} value of (4R,6R)-I was 0.88 nM. The invention compds. are claimed useful for the treatment of hypercholesterolemia, hyperlipidemia, etc. Pharmaceutical composition comprising (4R,6R)-I is disclosed.

IT 1221755-68-5P 1221755-71-0P 1221755-74-3P
 1221755-79-8P 1221755-85-6P 1221755-89-0P
 1221755-98-1P 1221756-06-4P 1221756-10-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic heteroaryl compds. as squalene synthase inhibitors)

RN 1221755-68-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-[3-methoxy-2-(trifluoromethyl)phenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1221755-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-[3-methoxy-2-(trifluoromethyl)phenyl]-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1221755-74-3 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(difluoromethyl)-6-[3-methoxy-2-(trifluoromethyl)phenyl]-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1221755-79-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-[3-ethoxy-2-(trifluoromethyl)phenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1221755-85-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-[3-ethoxy-2-(trifluoromethyl)phenyl]-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1221755-89-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-chloro-3-ethoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1221755-98-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-ethoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1221756-06-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-6-[3-ethoxy-2-(trifluoromethyl)phenyl]-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1221756-10-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-1-(chlorodifluoromethyl)-6-[3-ethoxy-2-(trifluoromethyl)phenyl]-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 1221756-75-7P 1221756-77-9P 1221756-78-0P
 1221756-94-0P 1221757-02-3P 1221757-17-0P
 1221757-36-3P 1221757-55-6P 1221757-59-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tricyclic heteroaryl compds. as squalene synthase inhibitors)

RN 1221756-75-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-[3-methoxy-2-(trifluoromethyl)phenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1221756-77-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-[3-methoxy-2-(trifluoromethyl)phenyl]-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1221756-78-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(difluoromethyl)-6-[3-methoxy-2-(trifluoromethyl)phenyl]-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1221756-94-0 CAPLUS


CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-[3-ethoxy-2-(trifluoromethyl)phenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1221757-02-3 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-[3-ethoxy-2-(trifluoromethyl)phenyl]-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1221757-17-0 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-chloro-3-ethoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1221757-36-3 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-ethoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1221757-55-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-6-[3-ethoxy-2-(trifluoromethyl)phenyl]-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1221757-59-0 CAPLUS



CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-1-(chlorodifluoromethyl)-6-[3-ethoxy-2-(trifluoromethyl)phenyl]-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2010:475284 CAPLUS Full-text
 DN 152:454154
 TI Preparation of substituted tricyclic heteroaryl compound as squalene and
 cholesterol synthetase inhibitors
 IN Sugita, Kazuyuki; Haginoya, noriyasu
 PA Daiichi Sankyo Co., Ltd., Japan
 SO PCT Int. Appl., 139pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2010041726 | A1 | 20100415 | WO 2009-JP67595 | 20091009 |
| | W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW, RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | JP 2008-263477 | A | 20081010 | | |
| OS | MARPAT 152:454154 | | | | |
| GI | | | | | |



AB Title compds. represented by the formula I [wherein R1 = (halo)alkoxy; R2 = halo, (halo)alkyl or alkoxy; R3 = halo, (halo)alkyl or (halo)alkoxy; R4 = hydroxyhaloalkyl; m = 0-4; -X-Y- = a single bond, alkylencarbonyl-heterocyclyl or alkylene-heterocyclyl; and pharmaceutically acceptable salts thereof] were prepared as squalene and cholesterol synthetase inhibitors. For example, II was provided in a multi-step synthesis starting from 2-bromo-3-hydroxybenzaldehyde. I were tested for inhibition of rat squalene synthetase and rat liver cholesterol synthetase, e.g. II had an IC50 value of 1.7 nM on squalene synthetase and 84% inhibition rate on cholesterol synthetase. Thus,

I are useful as squalene and cholesterol synthetase inhibitors for the treatment of hyperlipemia including hypercholesterolemia, hypertriglyceridemia and hypo-HDL cholesterolmia and/or arteriosclerosis in mammals including human.

IT 1221180-10-4P 1221180-12-6P 1221180-14-8P
1221180-16-0P 1221180-18-2P 1221180-20-6P
1221180-22-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of [1,2,4]triazolo[4,3-a]benzoxazepines as squalene and cholesterol synthetase inhibitors)

RN 1221180-10-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(1,1-difluoro-2-hydroxyethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1221180-12-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-methoxyphenyl)-1-(1,1-difluoro-2-hydroxyethyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1221180-14-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-ethoxyphenyl)-8-chloro-

1-(1,1-difluoro-2-hydroxyethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1221180-16-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(1,1-difluoro-2-hydroxyethyl)-6-[3-ethoxy-2-(trifluoromethyl)phenyl]-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1221180-18-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-chloro-3-ethoxyphenyl)-1-(1,1-difluoro-2-hydroxyethyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1221180-20-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-ethoxyphenyl)-1-(1,1-difluoro-2-hydroxyethyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1221180-22-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-1-(1,1-difluoro-2-hydroxyethyl)-6-[3-ethoxy-2-(trifluoromethyl)phenyl]-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 1221180-29-5P 1221180-38-6P 1221180-49-9P
 1221180-60-4P 1221180-70-6P 1221180-80-8P
 1221180-90-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of [1,2,4]triazolo[4,3-a]benzoxazepines as squalene and cholesterol synthetase inhibitors)

RN 1221180-29-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(1,1-difluoro-2-hydroxyethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1221180-38-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-methoxyphenyl)-1-(1,1-difluoro-2-hydroxyethyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1221180-49-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(1,1-difluoro-2-hydroxyethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 1221180-60-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(1,1-difluoro-2-hydroxyethyl)-6-[3-ethoxy-2-(trifluoromethyl)phenyl]-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1221180-70-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-chloro-3-ethoxyphenyl)-1-(1,1-difluoro-2-hydroxyethyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1221180-80-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-ethoxyphenyl)-1-(1,1-difluoro-2-hydroxyethyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1221180-90-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-1-(1,1-difluoro-2-hydroxyethyl)-6-[3-ethoxy-2-(trifluoromethyl)phenyl]-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:1459108 CAPLUS Full-text
 DN 149:576645
 TI Preparation of tricyclic compounds such as pyrrolobenzoxazepine
 derivatives and analogs thereof for treatment of hypercholesteremia,
 hyperlipemia, and arteriosclerosis
 IN Sugita, Kazuyuki; Otsuka, Masaki; Oki, Hitoshi; Haginoya, Noriyasu;
 Ichikawa, Masanori; Ito, Masao
 PA Daiichi Sankyo Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 1516pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | JP 2008291018 | A | 20081204 | JP 2008-114684 | 20080424 |
| PRAI | JP 2007-115119 | A | 20070425 | | |
| OS | MARPAT 149:576645 | | | | |
| GI | | | | | |




AB The title compds. [I; R1 = aryl or heteroaryl which may have 1 to 3
 substituents; R2, R2a = H, halo, cyano, etc.; R3 = H, halo, alkyl, etc.; R4 =
 carboxyl, carboxycarbonyl, carboxyalkenyl, etc.; X = CH2, O, S; Y = N, CR3a;
 R3a = same as defined for R3; Z = N, CR3aa; R3aa = same as defined for R3;
 ring (N) = benzene or pyridine ring] are prepared I inhibit squalene
 synthetase and cholesterol synthesis. Thus, 2-(2-(2-[(4R,6S)-8-chloro-6-(2,3-
 dimethoxyphenyl)-10-fluoro-4H,6H- pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl)-
 2H-1,2,3,4-tetrazol-5- yl)acetic acid was prepared in a multistep process
 starting from 2-bromo-4-chloro-6-fluoroaniline and 2,5-
 dimethoxytetrahydrofuran. Compds. of this invention showed IC50 values of 0.56
 nM to 7.6 nM against rat squalene synthetase.

IT 937062-05-0P
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical
 process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation of tricyclic compds. such as pyrrolobenzoxazepine derivs. and
 analogs thereof for treatment of hypercholesteremia, hyperlipemia, and
 arteriosclerosis)

RN 937062-05-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-
 (trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-
 yl]acetyl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 937064-87-4P 937064-93-2P 937064-94-3P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of tricyclic compds. such as pyrrolobenzoxazepine derivs. and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis)

RN 937064-87-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2,3-dimethoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937064-93-2 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[(4S,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(2,3-dimethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937064-94-3 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2,3-dimethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 937062-06-1P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tricyclic compds. such as pyrrolobenzoxazepine derivs. and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis)

RN 937062-06-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 937057-14-2P 937057-18-6P 937059-80-8P
 937060-09-8P 937061-74-0P 937062-64-1P
 937062-66-3P 937062-68-5P 937062-70-9P
 937062-72-1P 937062-74-3P 937062-75-4P
 937062-77-6P 937062-79-8P 937065-13-9P
 937065-15-1P 937065-44-6P 937066-16-5P
 937066-17-6P 937066-19-8P 937066-21-2P
 937066-23-4P 937066-25-6P 937071-03-9P
 937071-15-3P 937071-17-5P 937071-19-7P
 937071-27-7P 937071-34-6P 937071-36-8P
 937071-37-9P 937071-65-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of tricyclic compds. such as pyrrolobenzoxazepine derivs. and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis)

RN 937057-14-2 CAPLUS


CN 4-Piperidineacetic acid, 1-[3-[8-chloro-6-(2,3-dimethoxyphenyl)-1-methyl-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, ethyl ester (CA INDEX NAME)



RN 937057-18-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-methyl-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937059-80-8 CAPLUS


CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 937060-09-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)




RN 937061-74-0 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1,2-dimethyl-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-,

ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-64-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-66-3 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-68-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-70-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-72-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-74-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-75-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-77-6 CAPLUS

CN 3-Azetidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-79-8 CAPLUS

CN 3-Azetidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937065-13-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937065-15-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-cyano-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937065-44-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-[3-methoxy-2-(trifluoromethoxy)phenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-16-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-fluoro-3-methoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-17-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-chloro-3-methoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-19-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-1-(chlorodifluoromethyl)-6-(2-chloro-3-methoxyphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-21-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-chloro-3-methoxyphenyl)-1-(1,1-difluoroethyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-23-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2-chloro-3-methoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-25-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-methoxyphenyl)-1-(1,1-difluoroethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-03-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]-1-oxopropyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937071-15-3 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-17-5 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-19-7 CAPLUS

CN 3-Azetidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937071-27-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-34-6 CAPLUS


CN 1-Piperazinepropanoic acid, 4-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-2-oxo-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 937071-36-8 CAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-1-carboxylic acid,
 3-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 937071-37-9 CAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-1-carboxylic acid,
 3-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 937071-65-3 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-[3-methoxy-2-(trifluoromethoxy)phenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 937057-15-3P 937057-19-7P 937059-81-9P
 937060-10-1P 937060-11-2P 937061-60-4P
 937061-62-6P 937061-64-8P 937061-66-0P
 937061-72-8P 937061-76-2P 937061-78-4P
 937062-07-2P 937062-08-3P 937062-09-4P
 937062-65-2P 937062-67-4P 937062-69-6P
 937062-71-0P 937062-73-2P 937062-78-7P
 937062-80-1P 937062-88-9P 937062-89-0P
 937064-88-5P 937064-95-4P 937064-96-5P
 937065-14-0P 937065-16-2P 937065-45-7P
 937066-07-4P 937066-08-5P 937066-09-6P
 937066-10-9P 937066-11-0P 937066-12-1P
 937066-13-2P 937066-14-3P 937066-15-4P
 937066-18-7P 937066-20-1P 937066-22-3P
 937066-24-5P 937066-27-8P 937070-94-5P
 937070-95-6P 937071-04-0P 937071-16-4P
 937071-18-6P 937071-20-0P 937071-28-8P
 937071-35-7P 937071-66-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of tricyclic compds. such as pyrrolobenzoxazepine derivs. and
 analogs thereof for treatment of hypercholesteremia, hyperlipemia, and
 arteriosclerosis)

RN 937057-15-3 CAPLUS


CN 4-Piperidineacetic acid, 1-[3-[8-chloro-6-(2,3-dimethoxyphenyl)-1-methyl-
 4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]- (CA
 INDEX NAME)



RN 937057-19-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-methyl-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937059-81-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937060-10-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937060-11-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937061-60-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937061-62-6 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937061-64-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937061-66-0 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937061-72-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1,2-dimethyl-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937061-76-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1,2-dimethyl-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937061-78-4 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1,2-dimethyl-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-07-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4S,6R)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-08-3 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-09-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4S,6R)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-65-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-67-4 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-69-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-71-0 CAPLUS


CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 937062-73-2 CAPLUS
 CN 3-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 937062-78-7 CAPLUS
 CN 3-Azetidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 937062-80-1 CAPLUS
 CN 3-Azetidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-88-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2,3-dimethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-89-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2,3-dimethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937064-88-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2,3-dimethoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937064-95-4 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[(4S,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(2,3-dimethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937064-96-5 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2,3-dimethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937065-14-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937065-16-2 CAPLUS


CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-cyano-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 937065-45-7 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-[3-methoxy-2-(trifluoromethoxy)phenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 937066-07-4 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 937066-08-5 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-09-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-6-(3-methoxy-2-methylphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-10-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-6-(3-methoxy-2-methylphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-11-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-12-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-13-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-fluoro-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-14-3 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-fluoro-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-15-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-fluoro-3-methoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-18-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-chloro-3-methoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-20-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-1-(chlorodifluoromethyl)-6-(2-chloro-3-methoxyphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-22-3 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-chloro-3-methoxyphenyl)-1-(1,1-difluoroethyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-24-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2-chloro-3-methoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-27-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-methoxyphenyl)-1-(1,1-difluoroethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937070-94-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-10-methoxy-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937070-95-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-10-methoxy-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-04-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]-1-oxopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937071-16-4 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-18-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-20-0 CAPLUS

CN 3-Azetidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937071-28-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-35-7 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-2-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-66-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-[3-methoxy-2-(trifluoromethoxy)phenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:1339790 CAPLUS Full-text
 DN 149:534265
 TI Preparation of tricyclic heteroaryl compounds as squalene synthetase inhibitors
 IN Sugita, Kazuyuki; Ohtsuka, Masami; Oki, Hitoshi; Haginoya, Noriyasu; Ichikawa, Masanori; Ota, Masahiro; Shibata, Yoshihiro
 PA Daiichi Sankyo Co., Ltd., Japan
 SO PCT Int. Appl., 250pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2008132846 | A1 | 20081106 | WO 2008-JP1073 | 20080424 |
| | W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | JP 2010150142 | A | 20100708 | JP 2007-115164 | 20070425 |
| PRAI | JP 2007-115164 | A | 20070425 | | |
| GI | | | | | |



AB There are disclosed 31 specific compds. such as 2-[(4R,6S)-8-chloro-6-(2-chloro-3-ethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetic acid and (2) 2-(1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-ethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl)acetic acid which have a squalene synthase inhibition activity and a cholesterol synthesis inhibition activity and are useful as medicinal agents such as prophylactic and/or therapeutic agents for hyperlipemia (including hypercholesterolemia, hypertriglyceridemia and hypo-HDL-cholesterolemia) and/or arteriosclerosis in a mammal including human. Thus, Et [trans-5-(2-bromo-3-methoxyphenyl)-7-

chloro-2-thioxo- 1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetate was condensed with hydrazine hydrate in THF under ice-cooling for 30 min to give a hydrazone which was cyclocondensed with trifluoroacetic anhydride in dichloroethane first at room temperature for 2 h and then under refluxing for 2 h to give Et [trans-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H- [1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetate (I). Chromatog. resolution of I using a Chiralpak AD column and a 2:8 mixture of isopropanol and hexane as the eluent to give Et [(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H- [1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetate (II) and Et [(4S,6R)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H- [1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetate. II was stirred with a 4:1 mixture of AcOH and concentrated H₂SO₄ at 60° for 7 h to give [(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H- [1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetic acid (III). III showed IC₅₀ of 0.46 µM against squalene synthase and at 3 mg/kg in vivo inhibited by 98% the synthesis of cholesterol in the liver of rats after 1 h.

IT 1075688-01-5P, tert-Butyl
 2-[1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-ethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl]acetate 1075688-07-1P, tert-Butyl
 2-[1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2-chloro-3-ethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl]acetate 1075688-15-1P, tert-Butyl
 2-[1-[2-[(4R,6R)-8-chloro-6-(3-ethoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl]acetate 1075688-21-9P, tert-Butyl
 2-[1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-ethoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl]acetate 1075688-23-1P, tert-Butyl
 2-[1-[2-[(4R,6S)-6-(2,3-dimethoxyphenyl)-8-(trifluoromethoxy)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl]acetate 1075688-29-7P, tert-Butyl
 2-[1-[2-[(4R,6S)-8-chloro-6-[3-(difluoromethoxy)-2-methoxyphenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl]acetate 1075688-35-5P, tert-Butyl
 2-[1-[2-[(4R,6S)-8-chloro-6-(3-ethoxy-2-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl]acetate 1075688-38-8P, tert-Butyl
 2-[1-[[4R,6R)-8-chloro-6-(2-ethyl-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]piperidin-4-yl]acetate 1075688-39-9P,
 [1-[[4R,6R)-8-Chloro-6-(2-ethyl-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]piperidin-4-yl]acetic acid 1075688-52-6P, tert-Butyl
 2-[1-[[4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]piperidin-4-yl]acetate 1075688-63-9P, tert-Butyl
 2-[1-[2-[(4R,6R)-1-(1,1-difluoroethyl)-6-(3-methoxy-2-methylphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl]acetate 1075688-82-2P, Methyl
 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-3-pyrrolidinecarboxylate


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of tricyclic heteroaryl compds. as squalene synthetase inhibitors and cholesterol synthesis inhibitors)

RN 1075688-01-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-ethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-07-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2-chloro-3-ethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-15-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-ethoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-21-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-ethoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-23-1 CAPLUS


CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2,3-dimethoxyphenyl)-8-(trifluoromethoxy)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1075688-29-7 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-[3-(difluoromethoxy)-2-methoxyphenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1075688-35-5 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(3-ethoxy-2-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1075688-38-8 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(2-ethyl-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-39-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(2-ethyl-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-52-6 CAPLUS


CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1075688-63-9 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-1-(1,1-difluoroethyl)-6-(3-methoxy-2-methylphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1075688-82-2 CAPLUS
 CN 3-Pyrrolidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 1075688-02-6P 1075688-08-2P,
 2-[1-[2-[(4R,6S)-8-Chloro-1-(chlorodifluoromethyl)-6-(2-chloro-3-ethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl]acetic acid 1075688-16-2P,
 2-[1-[2-[(4R,6R)-8-Chloro-6-(3-ethoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl]acetic acid 1075688-22-0P,
 2-[1-[2-[(4R,6R)-8-Chloro-1-(chlorodifluoromethyl)-6-(3-ethoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl]acetic acid 1075688-24-2P,
 2-[1-[2-[(4R,6S)-6-(2,3-Dimethoxyphenyl)-8-(trifluoromethoxy)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-

yl]acetyl]-4-piperidinyl]acetic acid 1075688-30-0P,
 2-[1-[2-[(4R,6S)-8-Chloro-6-[3-(difluoromethoxy)-2-methoxyphenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl]acetic acid 1075688-36-6P,
 2-[1-[2-[(4R,6S)-8-Chloro-6-(3-ethoxy-2-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl]acetic acid 1075688-53-7P,
 [1-[[[(4R,6S)-6-(2-Bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]piperidin-4-yl]acetic acid 1075688-64-0P,
 2-[1-[2-[(4R,6R)-1-(1,1-Difluoroethyl)-6-(3-methoxy-2-methylphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl]acetic acid 1075688-83-3P,
 1-[2-[(4R,6R)-8-Chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-3-pyrrolidinecarboxylic acid


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic heteroaryl compds. as squalene synthetase inhibitors and cholesterol synthesis inhibitors)

RN 1075688-02-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-ethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-08-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2-chloro-3-ethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-16-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-ethoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-22-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-ethoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-24-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2,3-dimethoxyphenyl)-8-(trifluoromethoxy)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-30-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-[3-(difluoromethoxy)-2-methoxyphenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-36-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(3-ethoxy-2-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-53-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-64-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-1-(1,1-difluoroethyl)-6-(3-methoxy-2-methylphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1075688-83-3 CAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



```
OSC.G      1      THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT    45      THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```


L5 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2007:538026 CAPLUS Full-text
 DN 147:9956
 TI Preparation of tricyclic compounds such as pyrrolobenzoxazepine
 derivatives and analogs thereof for treatment of hypercholesteremia,
 hyperlipemia, and arteriosclerosis
 IN Sugita, Kazuyuki; Otsuka, Masami; Oki, Hitoshi; Haginoya, Noriyasu;
 Ichikawa, Masanori; Itoh, Masao
 PA Daiichi Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 1709pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|------------------|----------|
| PI | WO 2007055093 | A1 | 20070518 | WO 2006-JP321056 | 20061023 |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| | RW: | | | | |
| | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | EP 1939205 | A1 | 20080702 | EP 2006-832385 | 20061023 |
| | R: | | | | |
| | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| | US 20090181942 | A1 | 20090716 | US 2008-90870 | 20081003 |
| PRAI | JP 2005-306663 | A | 20051021 | | |
| | WO 2006-JP321056 | W | 20061023 | | |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 147:9956

GI



AB The title compds. I [R1 = aryl or heteroaryl which may have 1 to 3 substituents; R2, R2a = H, halo, cyano, etc.; R3 = H, halo, alkyl, etc.; R4 = carboxyl, carboxycarbonyl, carboxyalkenyl, etc.; X = CH2, O, S; Y = N, CR3a; R3a = same as defined for R3; Z = N, CR3aa; R3aa = same as defined for R3; ring (N) = benzene or pyridine ring] are prepared I inhibit squalene synthetase and cholesterol synthesis. Thus, 2-(2-(2-[(4R,6S)-8-chloro-6-(2,3-

dimethoxyphenyl)-10-fluoro-4H,6H- pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl)-2H-1,2,3,4-tetrazol-5-yl)acetic acid was prepared in a multistep process starting from 2-bromo-4-chloro-6-fluoroaniline and 2,5-dimethoxytetrahydrofuran. Compds. of this invention showed IC50 values of 0.56 nM to 7.6 nM against rat squalene synthetase.


IT 937062-05-0P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation of tricyclic compds. such as pyrrolobenzoxazepine derivs. and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis)

RN 937062-05-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.




IT 937064-87-4P 937064-93-2P 937064-94-3P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tricyclic compds. such as pyrrolobenzoxazepine derivs. and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis)

RN 937064-87-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2,3-dimethoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937064-93-2 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[(4S,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(2,3-dimethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937064-94-3 CAPLUS


CN 3-Piperidinecarboxylic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2,3-dimethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 937062-06-1P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of tricyclic compds. such as pyrrolobenzoxazepine derivs. and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis)
 RN 937062-06-1 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



| | | | |
|----|--------------|--------------|--------------|
| IT | 937057-14-2P | 937057-18-6P | 937059-80-8P |
| | 937060-09-8P | 937061-74-0P | 937062-64-1P |
| | 937062-66-3P | 937062-68-5P | 937062-70-9P |
| | 937062-72-1P | 937062-74-3P | 937062-75-4P |
| | 937062-77-6P | 937062-79-8P | 937065-13-9P |
| | 937065-15-1P | 937065-44-6P | 937066-16-5P |
| | 937066-17-6P | 937066-19-8P | 937066-21-2P |
| | 937066-23-4P | 937066-25-6P | 937071-03-9P |
| | 937071-15-3P | 937071-17-5P | 937071-19-7P |
| | 937071-27-7P | 937071-34-6P | 937071-36-8P |
| | 937071-37-9P | 937071-65-3P | |


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of tricyclic compds. such as pyrrolobenzoxazepine derivs. and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis)
 RN 937057-14-2 CAPLUS
 CN 4-Piperidineacetic acid, 1-[3-[8-chloro-6-(2,3-dimethoxyphenyl)-1-methyl-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, ethyl ester (CA INDEX NAME)



RN 937057-18-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-methyl-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937059-80-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937060-09-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, ethyl ester, rel- (CA INDEX NAME)


(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)



RN 937061-74-0 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1,2-dimethyl-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-64-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-66-3 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-68-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-70-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-72-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-74-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-75-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-77-6 CAPLUS

CN 3-Azetidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-79-8 CAPLUS

CN 3-Azetidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937065-13-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937065-15-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-cyano-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937065-44-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-[3-methoxy-2-(trifluoromethoxy)phenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-16-5 CAPLUS


CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-fluoro-3-methoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 937066-17-6 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-chloro-3-methoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 937066-19-8 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-1-(chlorodifluoromethyl)-6-(2-chloro-3-methoxyphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 937066-21-2 CAPLUS
 CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-chloro-3-methoxyphenyl)-1-(1,1-difluoroethyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-23-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2-chloro-3-methoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-25-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-methoxyphenyl)-1-(1,1-difluoroethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-03-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]-1-oxopropyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937071-15-3 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-17-5 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-19-7 CAPLUS

CN 3-Azetidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937071-27-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-34-6 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-2-oxo-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-36-8 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-1-carboxylic acid, 3-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-37-9 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-1-carboxylic acid, 3-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-65-3 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-[3-methoxy-2-(trifluoromethoxy)phenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




| | | | |
|----|--------------|--------------|--------------|
| IT | 937057-15-3P | 937057-19-7P | 937059-81-9P |
| | 937060-10-1P | 937060-11-2P | 937061-60-4P |
| | 937061-62-6P | 937061-64-8P | 937061-66-0P |
| | 937061-72-8P | 937061-76-2P | 937061-78-4P |
| | 937062-07-2P | 937062-08-3P | 937062-09-4P |
| | 937062-65-2P | 937062-67-4P | 937062-69-6P |
| | 937062-71-0P | 937062-73-2P | 937062-78-7P |
| | 937062-80-1P | 937062-88-9P | 937062-89-0P |
| | 937064-88-5P | 937064-95-4P | 937064-96-5P |
| | 937065-14-0P | 937065-16-2P | 937065-45-7P |
| | 937066-07-4P | 937066-08-5P | 937066-09-6P |
| | 937066-10-9P | 937066-11-0P | 937066-12-1P |
| | 937066-13-2P | 937066-14-3P | 937066-15-4P |
| | 937066-18-7P | 937066-20-1P | 937066-22-3P |
| | 937066-24-5P | 937066-27-8P | 937070-94-5P |
| | 937070-95-6P | 937071-04-0P | 937071-16-4P |
| | 937071-18-6P | 937071-20-0P | 937071-28-8P |
| | 937071-35-7P | 937071-66-4P | |

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic compds. such as pyrrolobenzoxazepine derivs. and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis)

RN 937057-15-3 CAPLUS


CN 4-Piperidineacetic acid, 1-[3-[8-chloro-6-(2,3-dimethoxyphenyl)-1-methyl-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]- (CA INDEX NAME)



RN 937057-19-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-methyl-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937059-81-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937060-10-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937060-11-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937061-60-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937061-62-6 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937061-64-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937061-66-0 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937061-72-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1,2-dimethyl-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937061-76-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1,2-dimethyl-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937061-78-4 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1,2-dimethyl-4H,6H-imidazo[1,2-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-07-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4S,6R)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-08-3 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-09-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4S,6R)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-65-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-67-4 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-69-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-73-2 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-78-7 CAPLUS

CN 3-Azetidineacetic acid, 1-[2-[(4R,6R)-8-chloro-6-(3-methoxy-2-methylphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-80-1 CAPLUS

CN 3-Azetidineacetic acid, 1-[2-[(4R,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937062-88-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2,3-dimethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937062-89-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2,3-dimethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937064-88-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2,3-dimethoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937064-95-4 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[(4S,6R)-8-chloro-1-(chlorodifluoromethyl)-6-(2,3-dimethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937064-96-5 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2,3-dimethoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937065-14-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-oxopropyl]-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937065-16-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-cyano-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937065-45-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-[3-methoxy-2-(trifluoromethoxy)phenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-07-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-08-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-09-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-6-(3-methoxy-2-methylphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-10-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-6-(3-methoxy-2-methylphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-11-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-12-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6R)-1-(chlorodifluoromethyl)-6-(3-methoxy-2-methylphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-13-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-fluoro-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-14-3 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-fluoro-3-methoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-15-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-fluoro-3-methoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-18-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-chloro-3-methoxyphenyl)-1,8-bis(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-20-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-1-(chlorodifluoromethyl)-6-(2-chloro-3-methoxyphenyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-22-3 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-6-(2-chloro-3-methoxyphenyl)-1-(1,1-difluoroethyl)-8-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-24-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-1-(chlorodifluoromethyl)-6-(2-chloro-3-methoxyphenyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937066-27-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-methoxyphenyl)-1-(1,1-difluoroethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937070-94-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-10-methoxy-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937070-95-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-10-methoxy-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-04-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]-1-oxopropyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937071-16-4 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-18-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-20-0 CAPLUS

CN 3-Azetidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937071-28-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-35-7 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]-2-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 937071-66-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(4R,6S)-8-chloro-6-[3-methoxy-2-(trifluoromethoxy)phenyl]-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzothiazepin-4-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2005:673302 CAPLUS Full-text
 DN 143:172909
 TI Preparation of tricyclic benzazepines as squalene synthase inhibitors used
 for the treatment of cardiovascular diseases
 IN Woltering, Elisabeth; Haerter, Michael; Flessner, Timo; Jeske, Mario;
 Griebenow, Nils; Suessmeier, Frank; Bischoff, Hilmar; Raabe, Martin;
 Buchmueller, Anja; Kolkhof, Peter; Ellinghaus, Peter; Weber, Olaf
 PA Bayer Healthcare A.-G., Germany
 SO PCT Int. Appl., 138 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|----------------------|----------|
| PI | WO 2005068472 | A1 | 20050728 | WO 2004-EP14871 | 20041231 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | DE 102004001871 | A1 | 20050901 | DE 2004-102004001871 | 20040114 |
| | AU 2004313695 | A1 | 20050728 | AU 2004-313695 | 20041231 |
| | CA 2553202 | A1 | 20050728 | CA 2004-2553202 | 20041231 |
| | EP 1706413 | A1 | 20061004 | EP 2004-804456 | 20041231 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| | CN 1926143 | A | 20070307 | CN 2004-80042450 | 20041231 |
| | BR 2004018404 | A | 20070515 | BR 2004-18404 | 20041231 |
| | JP 2007517817 | T | 20070705 | JP 2006-548183 | 20041231 |
| | IN 2006DN03958 | A | 20070427 | IN 2006-DN3958 | 20060710 |
| | MX 2006007981 | A | 20061019 | MX 2006-7981 | 20060712 |
| | ZA 2006005748 | A | 20071031 | ZA 2006-5748 | 20060712 |
| | KR 2006124683 | A | 20061205 | KR 2006-7014101 | 20060713 |
| | US 20090215743 | A1 | 20090827 | US 2009-586023 | 20090217 |
| PRAI | DE 2004-102004001871 | A | 20040114 | | |
| | WO 2004-EP14871 | W | 20041231 | | |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 143:172909

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Z = (CH₂)_n; n = 1-3; A = aryl, heteroaryl, etc.; X = O, S, NR₅; R₅ = H, alkyl; Y = N, CR₆; R₆ = H, OH, alkyl; R₁, R₂ = H, halo, CN, etc.; R₃ = alkyl, alkenyl, alkynyl, etc.; R₄ = OR₇, NR₈R₉; R₇ = H, alkyl; R₈, R₉ = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, condensation of thioamide II and acetyl hydrazine afforded tricyclic benzazepine III in 49% yield. In squalene synthase inhibition assays, compds. I exhibited IC₅₀ values <10 µM.

IT 1064250-47-0 1064250-48-1 1064250-49-2
 1064250-55-0 1064250-58-3 1064250-60-7


1064250-67-4

RL: PRPH (Prophetic)

(Preparation of tricyclic benzazepines as squalene synthase inhibitors
used for the treatment of cardiovascular diseases)


RN 1064250-47-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1064250-48-1 CAPLUS

CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(2-hydroxy-1,1-dimethylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(3-hydroxy-1-pyrrolidinyl)- (CA INDEX NAME)




RN 1064250-49-2 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1064250-55-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 1064250-58-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1064250-60-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 1064250-67-4 CAPLUS

CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(2-methoxy-1,1-dimethylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(3-hydroxy-1-pyrrolidinyl)- (CA INDEX NAME)




IT 860652-09-1P 860652-15-9P 860652-16-0P
 860652-17-1P 860652-18-2P 860652-19-3P
 860652-20-6P 860652-22-8P 860652-23-9P
 860652-24-0P 860652-25-1P 860652-26-2P
 860652-27-3P 860652-28-4P 860652-29-5P
 860652-30-8P 860652-31-9P 860652-32-0P
 860652-33-1P 860652-34-2P 860652-35-3P
 860652-36-4P 860652-37-5P 860652-40-0P
 860652-41-1P 860652-42-2P 860652-46-6P
 860652-51-3P 860652-56-8P 860652-65-9P
 860652-66-0P 860652-67-1P 860652-70-6P
 860652-85-3P 860652-86-4P 860652-87-5P
 860652-88-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic benzazepines as squalene synthase inhibitors used for the treatment of cardiovascular diseases)


RN 860652-09-1 CAPLUS

CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(1-piperidinyl)- (CA INDEX NAME)




RN 860652-15-9 CAPLUS

CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 860652-16-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)




RN 860652-17-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)




RN 860652-18-2 CAPLUS

CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(4-hydroxy-1-piperidinyl)-
(CA INDEX NAME)




RN 860652-19-3 CAPLUS

CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(4-morpholinyl)-
(CA INDEX NAME)



RN 860652-20-6 CAPLUS


CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(4-methyl-1-piperidinyl)-
(CA INDEX NAME)



RN 860652-22-8 CAPLUS

CN D-Proline, 1-[[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 860652-23-9 CAPLUS


CN D-Proline, 1-[[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 860652-24-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)




RN 860652-25-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, (CA INDEX NAME)



RN 860652-26-2 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)



RN 860652-27-3 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-

methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-
(CA INDEX NAME)




RN 860652-28-4 CAPLUS

CN 2-Pyrrolidinone, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-
4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX
NAME)



RN 860652-29-5 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-
methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-,
methyl ester (CA INDEX NAME)



RN 860652-30-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-
methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-


(CA INDEX NAME)



RN 860652-31-9 CAPLUS


CN L-Proline, 1-[[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860652-32-0 CAPLUS


CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(3-thiazolidinyl)- (CA INDEX NAME)



RN 860652-33-1 CAPLUS


CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 860652-34-2 CAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 860652-35-3 CAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)




RN 860652-36-4 CAPLUS

CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(3-hydroxy-1-pyrrolidinyl)-
(CA INDEX NAME)




RN 860652-37-5 CAPLUS

CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(1,1-dioxido-3-thiazolidinyl)- (CA INDEX NAME)




RN 860652-40-0 CAPLUS

CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)



RN 860652-41-1 CAPLUS


CN Ethanone, 1-(4-acetyl-1-piperazinyl)-2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]- (CA INDEX NAME)



RN 860652-42-2 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 860652-46-6 CAPLUS

CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(2-methoxyethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(1-piperidinyl)- (CA INDEX NAME)




RN 860652-51-3 CAPLUS

CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(methoxymethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(1-piperidinyl)- (CA INDEX NAME)




RN 860652-56-8 CAPLUS

CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(hydroxymethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(1-piperidinyl)- (CA INDEX NAME)




RN 860652-65-9 CAPLUS

CN 2-Piperazinone, 4-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)




RN 860652-66-0 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, ethyl ester (CA INDEX NAME)




RN 860652-67-1 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]- (CA INDEX NAME)



RN 860652-70-6 CAPLUS


CN Ethanone, 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(2-hydroxy-1,1-dimethylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)



RN 860652-85-3 CAPLUS

CN Ethanone, 2-[(4R,6R)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(4-methyl-1-piperidiny)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 860652-86-4 CAPLUS

CN Ethanone, 2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]-1-(4-methyl-1-piperidiny)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 860652-87-5 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[2-[(4R,6R)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 860652-88-6 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(1-methylethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
 RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d l2; d his; log y
L2 HAS NO ANSWERS
L1 STR
```



```
G1 O,S,N
G2 C,N
```

Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 00:39:17 ON 29 SEP 2010)

FILE 'REGISTRY' ENTERED AT 00:40:53 ON 29 SEP 2010

```
L1 STRUCTURE UPLOADED
L2 QUE L1
L3 7 S L2
L4 206 S L2 FUL
```

FILE 'CAPLUS' ENTERED AT 00:41:32 ON 29 SEP 2010

```
L5 8 S L4
```

| | | |
|--|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 47.48 | 239.68 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | -6.80 | -6.80 |

STN INTERNATIONAL LOGOFF AT 00:42:46 ON 29 SEP 2010